Skip to content

Impact of Fospropofol on Alkaline Phosphatase Levels and Postoperative Lipid Profiles in High Body Mass Index Patients

Impact of Fospropofol on Alkaline Phosphatase Levels and Postoperative Lipid Profiles in High Body Mass Index Patients

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101725
Enrollment
Unknown
Registered
2025-04-29
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative changes of lipid metabolism in patients with high body mass index

Interventions

Fospropofol group:Application of Fospropofol Disodium for Sedation in General Anesthesia
Propofol group:Application of Propofol Disodium for Sedation in General Anesthesia

Sponsors

Chengdu Integrated TCM&Westem Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Sixty patients undergoing elective general anesthesia for non-cardiac and non-liver surgery, age range 18-80 years old, BMI: >=25 kg/m^2.

Exclusion criteria

Exclusion criteria: 1. Known drug allergy: Patients allergic to propofol or fospropofol disodium; Patients allergic to other anesthetics or adjuvant drugs used in the study. 2. Severe systemic diseases: patients with significant liver dysfunction (e. g., Child-Pugh classification class B or C); Patients with renal insufficiency (e. g., GFR8%); severe thyroid dysfunction (for example, patients with uncontrolled hyperthyroidism or hypothyroidism); Patients with diagnosed metabolic syndrome. 4. Special physiological status: pregnant or lactating women; patients with recent (within the past 6 months) history of major trauma or surgery. 5. Use of drugs that affect lipid metabolism: long-term use of steroids or other drugs that may affect lipid metabolism (eg, steroids, statins); patients using immunosuppressants (eg, cyclosporine, tacrolimus). 6. Mental illness or substance abuse: Patients with severe mental illness (e. g., major depression, schizophrenia); patients with a history of drug or alcohol abuse in the past 6 months. 7. Other: patients who are unable or unwilling to comply with the study protocol; patients who have participated in other clinical trials within the past 1 month.

Design outcomes

Primary

MeasureTime frame
Liver function (ALT, AST, ALP, bilirubin);Lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides);Renal function;

Secondary

MeasureTime frame
Blood routine;HbA1c;Anesthesia quality assessment;

Countries

China

Contacts

Public ContactHuang Cuiyuan

Chengdu Integrated TCM&Westem Medicine Hospital

hcyroy@qq.com+86 183 8103 2693

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 2, 2026